Lisata Therapeutics to Release FY2025 Q2 Earnings on August 7 After-Market (EST), Forecast EPS -0.65 USD

Brief Summary

Lisata Therapeutics is expected to report Q2 2025 earnings with no revenue and an EPS of -0.65 USD after market close on August 7, 2025.

Impact of The News

The expectation for Lisata Therapeutics’ Q2 2025 earnings is highly negative, with an anticipated EPS of -0.65 USD and zero revenue. This performance is notably poor when compared with the earnings results of other tech companies like Apple and Microsoft, which have shown strong earnings and revenue growth in their respective quarters Wallstreetcn+ 2. For instance, Apple’s Q3 revenue reached 94.04 billion USD with an EPS of 3.65 USD, exceeding market expectations Wallstreetcn+ 2. High-tech companies like Qualcomm and Robinhood also demonstrate positive earnings growth, with Qualcomm reporting a Q3 revenue of 103.6 billion USD and Robinhood’s Q2 revenue growing by 45% Sina Finance. This stark contrast highlights Lisata Therapeutics’ underperformance relative to industry peers. Given this context, investors may perceive Lisata Therapeutics’ financial health and business prospects pessimistically, potentially leading to a decline in stock price post-earnings announcement. The persistent negative earnings might also impact future funding and investment in the company, which could further hinder its business development and growth trajectory.